Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Randomized, Double-blind, Placebo-controlled Study of Ascending Doses of WVE-007 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults Living With Overweight or Obesity

NCT06842186 is registered in ClinicalTrials.gov with Wave Life Sciences USA, Inc. as lead sponsor.

NCT NCT06842186
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06842186 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Randomized, Double-blind, Placebo-controlled Study of Ascending Doses of WVE-007 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults Living With Overweight or Obesity
Lead sponsor
Wave Life Sciences USA, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 31, 2025
Completion date
December 31, 2027
Enrollment
296 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

overweight and obesity